Legend Biotech

Youtube Subscribe

Open: 63.8 Close: 64.56 Change: 0.76

You're running out of time to find out about Legend Biotech Company Inc using an AI.

The game is changing. There is a new strategy to evaluate Legend Biotech fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Legend Biotech are: Legend, Biotech, receive, cell, payment, clinical, CART, …

Concept Map

Semantic Network

Stock Summary

Legend Biotech Corporation is a clinical-stage biopharmaceutical company. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM) The company also.

Today's Summary

Legend Biotech is initiating clinical development of LB2102 for the treatment of extensive stage small cell lung cancer and large cell neuroendocrine carcinoma. The preclinical evidence shows that an autologous CAR-T could be a differentiated treatment option for patients with small cell cancer. Novartis Pharma has signed an exclusive worldwide licence agreement for Legend Biotechnology.

Today's News

Legend Biotech will receive a $100 million upfront payment and will be eligible to receive up to $1.01 billion in clinical, regulatory and commercial milestone payments and tiered royalties. Legend Biotech is initiating clinical development of LB2102 for the treatment of extensive stage small cell lung cancer and large cell neuroendocrine carcinoma. The preclinical evidence shows that an autologous CAR-T could be a differentiated treatment option for patients with small cell cancer. Legend Biotech will conduct a Phase 1 clinical trial for LB2102 in the U.S. Under the terms of the License Agreement, Legend Biotechnology will receive a $100 million upfront payment and will be eligible to receive up to $1.01 billion. Legend Biotech USA Somerset, New Jersey, is seeking Sr. Clinical Research Scientist. Legend Biotech is seeking Autoimmune Research Scientist (Multiple Levels) in Nanjing, China. CAR-T Technology Platforms Scientist is part of the R&D team. Legend Biotech is a biotechnology company dedicated to treating life-threatening diseases. The company has signed a deal granting Novartis the rights to develop, manufacture and commercialize certain DLL3-directed CAR-T cell therapies. Bank of New York Mellon Corp Sells 7,992 Shares of Legend Biotech. Legend Biotech is a commercial-stage biotechnology company with a focus on the development and manufacturing of novel therapies. Novartis Pharma has signed an exclusive worldwide licence agreement  for Legend Biotechnology. Legend Biotech is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. Recent earnings estimate revisions suggest that good things are ahead for Legend. One of those therapies an early-stage program that goes after a promising target.

Stock Profile

"Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia , gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation."

Keywords

Are looking for the most relevant information about Legend Biotech? Investor spend a lot of time searching for information to make investment decisions in Legend Biotech. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Legend Biotech are: Legend, Biotech, receive, cell, payment, clinical, CART, and the most common words in the summary are: legend, biotech, stock, job, market, new, therapy, . One of the sentences in the summary was: Legend Biotech is initiating clinical development of LB2102 for the treatment of extensive stage small cell lung cancer and large cell neuroendocrine carcinoma. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #legend #biotech #stock #job #market #new #therapy.

Read more →

Youtube Subscribe

---